Cargando…

Long-Term Efficacy of Anti-Tumor Necrosis Factor Agents in Pediatric Luminal Crohn's Disease: A Systematic Review of Real-World Evidence Studies

PURPOSE: To determine the long-term efficacy of the anti-tumor necrosis factor (TNF) agents, infliximab (IFX) and adalimumab (ADA), in pediatric luminal Crohn's disease (CD) by performing a systematic literature review. METHODS: An electronic search was performed in Medline, Embase, and the Coc...

Descripción completa

Detalles Bibliográficos
Autores principales:	van Rheenen, Hanna, van Rheenen, Patrick Ferry
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	The Korean Society of Pediatric Gastroenterology, Hepatology and Nutrition 2020
Materias:	Systemic Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7073369/ https://www.ncbi.nlm.nih.gov/pubmed/32206624 http://dx.doi.org/10.5223/pghn.2020.23.2.121

Ejemplares similares

Ustekinumab trough levels in children with Crohn’s disease refractory to anti-tumor necrosis factor agents: a prospective case series of off-label use
por: Bouhuys, Marleen, et al.
Publicado: (2023)

De-Escalation of Anti-Tumor Necrosis Factor Alpha Agents and Reduction in Adverse Effects: A Systematic Review
por: Bouhuys, Marleen, et al.
Publicado: (2022)

Long-term clinical and real-world experience with Crohn’s disease treated with anti-tumor necrosis factor-α antibodies
por: Otake, Haruka, et al.
Publicado: (2022)

Exploring the Challenges of Implementing a Web-Based Telemonitoring Strategy for Teenagers With Inflammatory Bowel Disease: Empirical Case Study
por: Dijkstra, Alie, et al.
Publicado: (2019)

Real world analysis on the efficacy and safety of anti-tumor necrosis factor therapy in patients with stricturing Crohn’s disease
por: Vuyyuru, Sudheer K., et al.
Publicado: (2021)

The Long-Term Effect of Early Anti-Tumor Necrosis Factor on Restoration of Growth in Pediatric Crohn’s Disease
por: Shim, Jung Ok, et al.
Publicado: (2018)

Infliximab vs adalimumab: Points to consider when selecting anti-tumor necrosis factor agents in pediatric patients with Crohn’s disease
por: Kim, Eun Sil, et al.
Publicado: (2023)

Granulomatous interstitial nephritis and Crohn's disease
por: Timmermans, Sjoerd A.M.E.G., et al.
Publicado: (2016)

Calprotectin instability may lead to undertreatment in children with IBD
por: Haisma, Sjoukje-Marije, et al.
Publicado: (2020)

Gamma‐glutamyl transferase and disease course in pediatric‐onset primary sclerosing cholangitis: A single‐center cohort study
por: Berhane, Besrat, et al.
Publicado: (2023)

Long‐term effectiveness of ustekinumab comparable to antitumor necrosis factor agents in patients with Crohn's disease
por: Shiga, Hisashi, et al.
Publicado: (2022)

Long-term effectiveness and safety of ustekinumab in bio-naïve and bio-experienced anti-tumor necrosis factor patients with Crohn’s disease: a real-world multicenter Brazilian study
por: Parra, Rogério Serafim, et al.
Publicado: (2022)

Managing abnormal liver tests in children with inflammatory bowel disease
por: van Rheenen, Patrick F.
Publicado: (2021)

Efficacy of restarting anti-tumor necrosis factor α agents after surgery in patients with Crohn's disease
por: Hiraoka, Sakiko, et al.
Publicado: (2018)

Ustekinumab Versus Anti-tumour Necrosis Factor Alpha Agents as Second-Line Biologics in Crohn's Disease
por: Eriksson, Carl, et al.
Publicado: (2023)

Canadian Association of Gastroenterology Clinical Practice Guideline for the Medical Management of Pediatric Luminal Crohn’s Disease
por: Mack, David R, et al.
Publicado: (2019)

Neural response during temporal – and spatial luminance contrast processing and its manifestation in the blood-oxygen-level-dependent-signal in striate and extra-striate cortex
por: Marcar, Valentine L., et al.
Publicado: (2021)

Diverse transcriptional regulation and functional effects revealed by CRISPR/Cas9-directed epigenetic editing
por: Vizoso, Miguel, et al.
Publicado: (2021)

No association between abdominal pain and Dientamoeba in Dutch and Belgian children
por: Brands, Martijn Ramon, et al.
Publicado: (2019)

Rare and Serious Adverse Effects of Anti-Tumor Necrosis Factor-Alpha (TNF-α) Agents in Crohn’s Disease
por: Kim, Sun, et al.
Publicado: (2021)

Imaging windows for long-term intravital imaging: General overview and technical insights
por: Alieva, Maria, et al.
Publicado: (2014)

A186 CHANGES IN THE CLINICAL PHENOTYPE AND BEHAVIOR OF PEDIATRIC LUMINAL CROHN’S DISEASE AT DIAGNOSIS IN THE LAST DECADE
por: Sassine, S, et al.
Publicado: (2022)

Factors associated with time to clinical remission in pediatric luminal Crohn's disease: A retrospective cohort study
por: Sassine, Samuel, et al.
Publicado: (2021)

Understanding Is Key: An Analysis of Factors Pertaining to Trust in a Real-World Automation System
por: Balfe, Nora, et al.
Publicado: (2018)

Long‐term outcomes of anti‐tumor necrosis factor therapy and surgery in nonperianal fistulizing Crohn's disease
por: Vuyyuru, Sudheer K, et al.
Publicado: (2021)

Effect of faecal calprotectin testing on referrals for children with chronic gastrointestinal symptoms in primary care: study protocol for a cluster randomised controlled trial
por: Ansems, Sophie, et al.
Publicado: (2021)

Fatigue in children and adolescents with inflammatory bowel disease
por: Van de Vijver, Els, et al.
Publicado: (2019)

Long-Term Real-World Effectiveness and Safety of Ustekinumab in Crohn’s Disease Patients: The SUSTAIN Study
por: Chaparro, María, et al.
Publicado: (2022)

Association between Fecal Calprotectin and Mucosal Healing in Pediatric Patients with Crohn’s Disease Who Have Achieved Sustained Clinical Remission with Anti-Tumor Necrosis Factor Agents
por: Lee, Yoo Min, et al.
Publicado: (2022)

A188 FACTORS ASSOCIATED WITH CLINICAL REMISSION IN PEDIATRIC LUMINAL CROHN’S DISEASE: A RETROSPECTIVE COHORT STUDY
por: Sassine, S, et al.
Publicado: (2022)

A187 RISK FACTORS OF CLINICAL RELAPSES IN PEDIATRIC LUMINAL CROHN’S DISEASE, A RETROSPECTIVE COHORT STUDY
por: Sassine, S, et al.
Publicado: (2022)

Chaos: the world of nonperiodic oscillations
por: Rössler, Otto E, et al.
Publicado: (2020)

Epithelial-to-Mesenchymal Transition in the Light of Plasticity and Hybrid E/M States
por: Bornes, Laura, et al.
Publicado: (2021)

Real-world clinical effectiveness and safety of vedolizumab and anti-tumor necrosis factor alpha treatment in ulcerative colitis and Crohn’s disease patients: a German retrospective chart review
por: Helwig, Ulf, et al.
Publicado: (2020)

Factors Contributing to the Preference of Korean Patients with Crohn’s Disease When Selecting an Anti-Tumor Necrosis Factor Agent (CHOICE Study)
por: Kim, Eun Soo, et al.
Publicado: (2016)

Correlation of serum levels of anti-tumor necrosis factor agents with perianal fistula healing in Crohn’s disease: a narrative review
por: Miranda, Eron Fabio, et al.
Publicado: (2021)

Stock market dynamics created by interacting agents
por: Eisele, K T, et al.
Publicado: (1995)

3rd World Congress on Nonlinear Analysis
Publicado: (2000)

Perianal and Luminal Relapse Following Perianal Surgical Intervention in Crohn’s Disease
por: Deng, Feihong, et al.
Publicado: (2021)

Prognostic factors for the efficacy of infliximab in patients with luminal fistulizing Crohn’s disease
por: Ma, Ye, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_2oaju5590upr9nhtuh3eq43sf1